How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. (Q38060224)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

0 references

0 references

0 references

author name string

S A Brown

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

C Barnes

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

J Curtin

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

S Dunkley

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

P Ockelford

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

J Phillips

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

J Rowell

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

M Smith

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

H Tran

9

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Hematology working group

10

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

1 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Internal Medicine Journal

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

42

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1243-1250

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Inhibitor development in haemophilia B: an orphan disease in need of attention

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Epidemiology of inhibitors in haemophilia A.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

First 20 years with recombinant FVIIa (NovoSeven).

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

The use of recombinant factor VIIa in the treatment of bleeding disorders.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Health economics in haemophilia: a review from the clinician's perspective

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Importance of rapid bleeding control in haemophilia complicated by inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg−1 in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008)

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Prophylaxis in haemophilia with inhibitors: update from international experience

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

European study on orthopaedic status of haemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

rFVIIa transported from the blood stream into tissues is functionally active.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Co-morbidities and quality of life in elderly persons with haemophilia

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

The need for speed in the management of haemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Management of difficult-to-treat inhibitor patients

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Orthopaedic surgery in haemophilic patients with inhibitors: an overview

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Elective orthopaedic surgery for inhibitor patients

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes

1 reference

https://api.crossref.org/works/10.1111/J.1445-5994.2012.02942.X

21 January 2018

Identifiers

10.1111/J.1445-5994.2012.02942.X

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38060224&oldid=1511263219"